3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Unknown
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Urologic Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Intraductal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Hemorrhage
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Advanced Ovarian Cancer
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
34
Specimen Handling
18
Paclitaxel
16
Magnetic Resonance Spectroscopy
15
Carboplatin
14
Biopsy
14
Nivolumab
13
Ipilimumab
12
Gemcitabine
10
Irinotecan
9
Radiosurgery
8
atezolizumab
7
abemaciclib
7
Radiation
7
Pemetrexed
7
Cisplatin
7
Capecitabine
7
130-nm albumin-bound paclitaxel
7
trastuzumab deruxtecan
6
olaparib
6
durvalumab
6
avelumab
6
Docetaxel
6
osimertinib
5
adagrasib
5
Trastuzumab
5
Fulvestrant
5
Cetuximab
5
Albumin-Bound Paclitaxel
5
palbociclib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasm Metastasis
×
Saline Solution
×
Clear all
NCT04895358
2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
340 enrolled